Clinical Trial Update: Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of vismodegib and atezolizumab for recurrent or metastatic non-small cell lung cancer; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Vismodegib (Vismodegib)

Snippet

Sponsor: Dwight Owen | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Status: RECRUITING